相关实验视频

Updated: May 5, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

预症状的向电路操纵,以改善亨廷顿病的发病因子

Ebenezer C Ikefuama¹, Ashley N Slaviero², Alexander D Silvagnoli¹

¹Program in Neuroscience, Central Michigan University, Mount Pleasant, MI 48859, USA.

|March 17, 2025

概括

针对早期亨廷顿病 (HD) 通过在症状出现之前调整大脑电路活动,可以减缓疾病的进展. 调节运动皮层中的特定神经元类型,在小鼠模型中改善了运动功能,提供了潜在的治疗策略.

科学领域:

神经科学是一个神经科学.
神经退行性疾病神经退行性疾病
分子生物学分子生物学

背景情况:

亨廷顿病 (HD) 在运动和认知症状出现之前,大脑电路中的刺激/抑制 (E/I) 失衡.
这种症状前的窗口为治疗干预提供了一个关键的机会,以恢复E / I平衡并减缓疾病的进展.

研究的目的:

研究细胞类型特异调节M1运动皮质活动对在症状前的疾病小鼠模型中疾病进展的影响.
为了确定抑制金字塔神经元激发或增加内部神经元活动是否可以缓解早期与疾病相关的缺陷.

主要方法:

利用了亨廷顿病的R6/2小鼠模型.
在前症状阶段,每天在M1运动皮层中对金字塔神经元 (Emx1) 和帕瓦尔胺内部神经元进行细胞类型特定的操纵,持续三周.
评估了对运动协调和疾病进展的影响.

主要成果:

抑制Emx1金字塔神经元刺激显著缓解了与HD相关的运动协调功能障碍.
增加帕瓦胺内部神经元活动也改善了在症状前的疾病发病小鼠模型中的运动缺陷.
这些发现表明,通过细胞类型特定调制来规范皮质输出在HD模型中是有效的.

结论:

皮质微电路的细胞类型特异调制代表了亨廷顿病的有前途的治疗策略.
在症状前阶段准E/I平衡可以预防或减缓HD运动缺陷的进展.
这种方法也可能适用于其他神经退行性疾病,其特点是电路功能障碍.

关键词:

细胞神经科学细胞神经科学分子神经科学分子神经科学

更多相关视频

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Single Synapse Indicators of Glutamate Release and Uptake in Acute Brain Slices from Normal and Huntington Mice

Published on: March 11, 2020

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...